Can This Forgotten Drug Save VIVUS Investors?
Nov 6th 2012 4:14PM
Updated Nov 6th 2012 4:18PM
The three main players in the obesity drug space -- VIVUS (NAS: VVUS) , Arena Pharmaceuticals (NAS: ARNA) , and Orexigen Therapeutics (NAS: OREX) -- are prepared to brave the market's reaction and release their Q3 results.
VIVUS, in fact, already reported its results before the market opened this morning, and sales from its flagship drug Qsymia fell short of expectations. Shares plunged 25% on this news, and investors are wondering if Qsymia realistically has the potential to reach blockbuster status.
Although VIVUS' obesity drug often takes the spotlight, the company actually has another FDA-approved drug in its portfolio. In the following video, health care analysts Max Macaluso and David Williamson discuss what this drug is and whether it might be able to surpass Qsymia's sales in the future.
The ravages of America's obesity epidemic are a challenge of epic proportions. However, newly approved drugs, including VIVUS' Qsymia, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.
The article Can This Forgotten Drug Save VIVUS Investors? originally appeared on Fool.com.Max Macaluso, Ph.D. has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.